<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22040">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819921</url>
  </required_header>
  <id_info>
    <org_study_id>WI209149</org_study_id>
    <nct_id>NCT02819921</nct_id>
  </id_info>
  <brief_title>Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen</brief_title>
  <official_title>Desvenlafaxine for the Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen: a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, placebo-controlled study of desvenlafaxine versus placebo. The
      purpose of this study is to determine if desvenlafaxine was effective in decreasing the
      frequency and severity of hot flashes in breast cancer patients taking tamoxifen.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Daily Number of Hot Flashes</measure>
    <time_frame>From baseline to Week 13 (Intervention is started from Week 1)</time_frame>
    <description>Participants would complete self -report daily diary on which they record the number hot flashes and severity of hot flashes from baseline to Week 13.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Daily Severity of Hot Flashes</measure>
    <time_frame>From baseline to Week 13 (Intervention is started from Week 1)</time_frame>
    <description>Participants would be instructed to fill out diaries at least daily and to characterize each hot flash as grade 1 (mild), 2 (moderate), 3 (severe), or 4 (very severe). The average daily severity of hot flashes for each week would be the sum of the daily severity scores divided by the number of days in that week with data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical impression state and change</measure>
    <time_frame>Baseline, Week 2, Week 7, Week 13</time_frame>
    <description>Clinical global impression (CGI) would be used to assess clinical impression state and change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline, Week 2, Week 7, Week 13</time_frame>
    <description>Patient health questionnaire (PHQ-9) would be used to assess mood status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>Baseline, Week 2, Week 7, Week 13</time_frame>
    <description>Hospital anxiety and depression scale (HADS) would be used to assess depression and anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Baseline, Week 2, Week 7, Week 13</time_frame>
    <description>Fatigue severity scale (FSS) would be used to assess fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Baseline, Week 2, Week 7, Week 13</time_frame>
    <description>Pittsburgh sleep quality index (PSQI) would be used to assess sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline, Week 2, Week 7, Week 13</time_frame>
    <description>Functional assessment of cancer therapy - breast (FACT-B) would be used to assess quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived cognition</measure>
    <time_frame>Baseline, Week 2, Week 7, Week 13</time_frame>
    <description>Functional assessment of cancer therapy - cognition (FACT-Cog) would be used to assess perceived cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal level</measure>
    <time_frame>Week 7</time_frame>
    <description>Serum estradiol level would be used to examine pathophysiological mechanisms associated with the presence of hot flashes, mood status and desvenlafaxine treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphism</measure>
    <time_frame>Week 7</time_frame>
    <description>estrogen receptors (ESR1 PvuII; rs#2234693 and XbaI; rs#9340799 and ESR2-02; rs#4986938) and serotonin transporter gene (SLC6A4; rs#11080121) would be used to examine pathophysiological mechanisms associated with the presence of hot flashes, mood status and desvenlafaxine treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily activity</measure>
    <time_frame>From baseline to Week 13 (Intervention is started from Week 1)</time_frame>
    <description>Wearable actigraphy would be used to assess psychophysiological patterns.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hot Flashes</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Desvenlafaxine succinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titration with 50 mg Desvenlafaxine succinate tablet once daily for 7 days, then 2 tablets of 50mg tablet once daily for 11 weeks, then taper with 50 mg tablet once daily for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Titration with 50 mg placebo tablet once daily for 7 days, then 2 tablets of 50mg placebo tablet once daily for 11 weeks, then taper with 50 mg placebo tablet once daily for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine succinate</intervention_name>
    <arm_group_label>Desvenlafaxine succinate</arm_group_label>
    <other_name>Pristiq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Women age 18 years and older with localized breast cancer. Histologic documentation of
        atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ
        (LCIS), or invasive adenocarcinoma of the breast stages I-III A.

        ii. Current daily tamoxifen use. Any planned surgery, adjuvant chemotherapy or radiation
        must have been completed.

        iii. History of bothersome hot flushes: â‰¥ 2 hot flushes/day, sufficiently severe that
        intervention is desired. Participants must have had bothersome hot flushes for at least
        one month prior to enrollment.

        Exclusion Criteria:

        i. Women who is pregnant or breast feeding, or who has a history of seizure disorder or
        hepatic or renal insufficiency ii. Concurrent systemic hormone replacement therapy
        (estrogen, progestational agents, androgens) or use of corticosteroids iii. Concurrent use
        of other antidepressants, anxiolytics and antipsychotics, gabapentin, pregabalin and
        clonidine for treatment of hot flushes or depression.

        iv. Presence of other psychiatric diseases beside of depression and any disease which can
        affect the immune system (autoimmune disease including rheumatoid disease)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bong-Jin Hahm, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kwang-Min Lee, M.D.</last_name>
    <phone>82-02-2072-3767</phone>
    <email>ceposto@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heesung Hwang, M.D.</last_name>
    <phone>82-02-2072-3767</phone>
    <email>mashinken@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kwang-Min Lee, M.D.</last_name>
      <phone>82-02-2072-3767</phone>
      <email>ceposto@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 28, 2016</lastchanged_date>
  <firstreceived_date>June 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hot Flashes</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Desvenlafaxine Succinate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
